Septerna (NASDAQ:SEPN) Upgraded at Zacks Research

Zacks Research upgraded shares of Septerna (NASDAQ:SEPN) from a strong sell rating to a hold rating in a research report released on Tuesday morning,Zacks.com reports.

Other equities analysts also recently issued reports about the company. HC Wainwright raised their price objective on Septerna from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. Truist Financial assumed coverage on shares of Septerna in a research report on Monday, December 15th. They set a “buy” rating and a $34.00 target price for the company. Raymond James Financial started coverage on Septerna in a research report on Friday, December 19th. They set a “strong-buy” rating and a $38.00 price target on the stock. Wall Street Zen lowered shares of Septerna from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $33.83.

Septerna Trading Up 1.0%

Shares of SEPN opened at $30.28 on Tuesday. The firm has a market capitalization of $1.36 billion, a P/E ratio of -20.05 and a beta of 3.85. The stock’s fifty day simple moving average is $26.96 and its 200 day simple moving average is $22.15. Septerna has a twelve month low of $4.66 and a twelve month high of $32.63.

Insider Buying and Selling

In related news, COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total value of $115,880.00. Following the completion of the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $5,046,834.73. This trade represents a 2.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its holdings in shares of Septerna by 86.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after acquiring an additional 1,260,409 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Septerna by 7.4% in the third quarter. Vanguard Group Inc. now owns 1,518,757 shares of the company’s stock worth $28,568,000 after purchasing an additional 104,394 shares during the period. Avoro Capital Advisors LLC increased its stake in Septerna by 8.1% during the third quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock valued at $25,158,000 after purchasing an additional 100,000 shares during the last quarter. ADAR1 Capital Management LLC grew its position in shares of Septerna by 38.9% during the 3rd quarter. ADAR1 Capital Management LLC now owns 1,176,491 shares of the company’s stock valued at $22,130,000 after buying an additional 329,264 shares during the last quarter. Finally, First Light Asset Management LLC acquired a new stake in Septerna during the fourth quarter worth about $17,308,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.